Symbolbild · KI-generiert
AbCellera Biologics Inc.
Stock factsheet
Company data from public sources (TMX Money, Canadian Securities Exchange, Nasdaq screener, Wikidata); every ISIN is verified against its check digit. Where „—“ appears, no verified value exists — we do not publish unverified identifiers. Market capitalisation is an order of magnitude as of the date shown, not a real-time figure. The size class follows the thresholds in common use (micro < $300m, small < $2bn, mid < $10bn) and is meant as an indication, not a definition.
Company profile
AbCellera is a Canadian biotechnology company operating an AI-driven antibody discovery platform for pharmaceutical partners. Its business model is based on collaboration agreements and royalties from medicines developed using AbCellera technology. The company gained prominence through its co-development of the COVID-19 antibody bamlanivimab.
Short profile generated automatically and checked for plausibility. A full editorial profile follows once we cover the company.
Share price
Price data from TradingView, possibly delayed. Not investment advice.
Comparable companies
Companies in the Biotech & Pharma sector of a similar size.
| Company | Ticker | Exchange | Market cap |
|---|---|---|---|
| AbCellera Biologics Inc. | ABCL | NASDAQ | 1,68 Mrd. USD |
| Taysha Gene Therapies, Inc. | TSHA | NASDAQ | 1,68 Mrd. USD |
| Syndax Pharmaceuticals, Inc. | SNDX | NASDAQ | 1,69 Mrd. USD |
| Maravai LifeSciences Holdings, Inc. | MRVI | NASDAQ | 1,70 Mrd. USD |
| NovoCure Limited | NVCR | NASDAQ | 1,73 Mrd. USD |
| Ascentage Pharma Group International American Depository Shares | AAPG | NASDAQ | 1,63 Mrd. USD |
| Immunocore Holdings plc | IMCR | NASDAQ | 1,63 Mrd. USD |
Investor Relations
We link only to primary sources from the company itself and from the regulators. Fields we have not recorded stay empty until a reliable source is available.
Information and education only — not investment advice, not a recommendation and not a financial analysis within the meaning of §85 WpHG or Art. 20 MAR. Investments in small and micro caps are highly speculative; total loss is possible. All information without warranty.